RBX7455

Phase 2Biologic

MMayo Clinic

RBX7455 is one of 69 biologic programs targeting Clostridium Difficile Infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Clostridium Difficile InfectionActive, not recruiting

EncephalopathyActive, not recruiting

Clostridium Difficile InfectionPhase 1

Active, not recruiting

EncephalopathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

135 competitors in Encephalopathy

#DrugCompanyPhaseTrials

Xifaxan

SSalix

Phase 3

21 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 3

Alinia

RRomark Laboratories L.C.

Phase 3

4 4

PROCRIT

WWim Janssens

Phase 3

3 5

Cafcit

KKaken Pharmaceutical

Phase 3

1 6

Aranesp

Amgen

Phase 2

3 7

Yescarta

Gilead

Phase 2

1 8

MS Contin

Merck & Co.

Phase 2

1 9

Fludara

Sanofi

Phase 2

1 10

Fludara

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Clostridium Difficile Infection1 trial

Treatment of Recurrent Clostridium Difficile Infection With RBX7455

Completed·MMayo Clinic·Phase 1·NCT02981316·30 enrolled

Encephalopathy1 trial

Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy

Terminated·OOchsner Health System·Phase 2·NCT04155099·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for RBX7455. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RBX7455 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RBX7455. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: MMayo Clinic

RBX7455

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Clostridium Difficile Infection1 trial

Encephalopathy1 trial

References

Drug Info

Quick Facts

Related News